MedTrace Logo

Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

NCT02011594 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2015-02-12

No results posted yet for this study

Summary

There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.

Conditions

  • Stage IV Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Nimotuzumab

400mg Q2W intravenously

DRUG

Placebo

Normal saline

Sponsors & Collaborators

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Qiong Zhao, PhD · First Affiliated Hospital,Zhejiang University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-01-31
Completion
2015-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02011594 on ClinicalTrials.gov